No Prescription |
 |
 | ||
|
Amizide Moduretic |
|
| ||
No Prescription » Prescription Drugs 1 » Amizide Moduretic AMIZIDE is used to treat high blood pressure. It can also be used to reduce fluid retention in people with heart or liver disease.AMIZIDE helps to reduce the amount of excess fluid in the body by increasing the amount of urine produced while at the same time helping to maintain normal potassium levels in the blood.AMIZIDE may be taken alone or in combination with other medicines to treat your condition. Buy Amizide Moduretic and other Prescription Drugs 1 products online at Medstore. Buy Online at Medstore - Click Here!
About Amizide Moduretic: Product Type: Prescription Drugs 1 Amizide (Moduretic Generic Amiloride/Hydrochlorothiazide ) Amizide (Moduretic Generic Amiloride/Hydrochlorothiazide) Moduretic Generic Amiloride/Hydrochlorothiazide 5/50mg 500 Tablets 1000(2 x 500) Tabs Moduretic Generic Amiloride/Hydrochlorothiazide Amizide
View more Prescription Drugs 1 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
